Rhythm Pharmaceuticals Announces FDA Acceptance for Priority Review of Supplemental New Drug Application for Imcivree® (Setmelanotide) in Patients as Young as 2 Years Old
rhythm pharmaceuticals宣佈美國食品藥品監督管理局接受優先評審補充新藥申請，用於2歲及以上患者的Imcivree® (Setmelanotide)
